Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 3 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
3 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.

COMET-2 falls short in showing palliative effect of cabozantinib in mCRPC

Audrey Abella
30 Sep 2019

Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.

Bone metastases in patients with mCRPC is often associated with debilitating pain and functional compromise. [J Clin Oncol 2008;26:2544-2549] Even with narcotic analgesics, pain related to osseous disease is often poorly controlled. [J Oncol Pract 2013;9:223-229] “[Durable] pain control [and pain relief] in men with symptomatic osseous metastases … remain critical unmet needs … in mCRPC,” said the researchers.

To establish the palliative effect of cabozantinib in mCRPC, researchers evaluated 119 men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after two or more lines of life-prolonging therapy (docetaxel and either abiraterone or enzalutamide). Participants were randomized 1:1 to receive either once-daily oral cabozantinib 60 mg or mitoxantrone 12 mg/m2 every 3 weeks (≤10 infusions) plus twice-daily oral prednisone 5 mg. The primary endpoint was pain response at week 6 confirmed at week 12**. Enrolment was terminated early due to the lack of survival benefit with cabozantinib in COMET-1***. [Eur Urol 2019;75:929-937]

The findings showed no significant difference in the rates of confirmed pain response between the cabozantinib and mitoxantrone-prednisone arms (15 percent vs 17 percent; p=0.8).

Compared with the mitoxantrone-prednisone arm, the cabozantinib arm had a higher incidence of grade 3/4 hypertension (22 percent vs 0 percent), fatigue (18 percent vs 8.8 percent), increased aspartate aminotransferase (10 percent vs 1.8 percent), diarrhoea (8.3 percent vs 1.8 percent), and decreased weight (5.0 percent vs 0 percent). Serious AEs were also more frequent among cabozantinib than mitoxantrone-prednisone recipients (72 percent vs 61 percent).

“Although this trial did not meet the primary endpoint, it provides valuable insights about the design and conduct of oncology trials assessing symptom control with patient-reported outcomes,” said the researchers.

The researchers underscored that the heavy pretreatment required and the presence of advanced disease, as well as the required washout and narcotic optimization periods, might have limited the findings. “[These factors] limited the pool of patients, particularly those with rapidly progressing disease who required immediate treatment.”

Therefore, patients with any level of pain should be eligible to participate in future trials with a composite endpoint assessing pain progression, palliation, and elimination, said the researchers. Moreover, washout and narcotic optimization periods should be shortened, they added.

Future pain palliation trials should incorporate briefer timelines from enrolment to treatment initiation … Multiple lines of prior therapy should also not be required because later-stage disease is more heterogeneous and less likely to respond to treatment. Pain and narcotic use should be assessed independently as well as together in an exploratory composite endpoint,” said the researchers.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 3 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
3 days ago
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.